JPRN-jRCTs031210290已完成2 期
Adding Radiotherapy to Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Phase II trial - AREnA trial
Yoshida Soichiro0 个研究点目标入组 50 人开始时间: 2021年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Patients with all of the following conditions will be eligible
- •1. 20 years of age or older and able to provide informed consent.
- •2. histologically or cytologically confirmed prostate cancer, without neuroendocrine, signet ring cell or small cell carcinoma
- •3. androgen deprivation therapy with GnRH agonist/antagonist or previous bilateral orchiectomy (drug or surgical castration) during the study period
- •4. testosterone level of less than 50 ng/dL at screening
- •5, patients with progressive disease who are on androgen deprivation therapy at the time of inclusion (disease progression is defined as three or more PSA increases at intervals of at least one week)
- •6, patients with a recent PSA level of 2 ng/mL or higher
- •7, PSA doubling time is less than 10 months
- •8. patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- •9. patients expected to survive for at least 1 year
- •10. patients with prostate and/or pelvic lymph node involvement confirmed by CT, MRI or bone scintigraphy performed as routine care within 3 months (prostate lesions are confirmed by MRI)
- •11. patients who are willing and able to follow the study protocol, including follow-up visits and examinations.
排除标准
- •A person is ineligible if he meets any of the following criteria.
- •1. patients who have received cytotoxic chemotherapy, aminoglutethimide, ketoconazole, olaparib, abiraterone acetate or enzalutamide for the treatment of prostate cancer
- •2. patients who have used the study drug within 4 weeks of the study start date
- •3. patients with a history of invasive cancer other than prostate cancer within 3 years of the study start date
- •4. patients with bone metastasis, visceral metastasis or distant lymph node metastasis confirmed by CT, MRI or bone scintigraphy performed as routine medical care within 3 months
- •5. neutrophil count less than 1,000,000/L, platelet count less than 100 x 1000,000,000/L and hemoglobin less than 10g/dL at screening
- •6. patients with total bilirubin more than 1.5 times the upper limit of normal (ULN), ALT and AST more than 2.5 times ULN at screening
- •7, patients with creatinine greater than 2 mg/dL at screening.
- •8, patients with albumin less than 3.0 g/dL at screening.
- •9, patients with a history of convulsive seizures or conditions that precipitate convulsive seizures.
- •10, patients with clinically significant cardiovascular disease.
- •11, patients with gastrointestinal diseases that affect absorption
- •12, patients who have undergone major surgery within 4 weeks of the study start date.
- •13. patients with hypersensitivity to the pharmaceutical ingredients, including labrasol, butylated hydroxyanisole, and butylated hydroxytoluene
- •14. patients with conditions or circumstances that, in the judgment of the investigator, would place the patient at undue risk, interfere with the completion of the study, or interfere with the analysis of the study results
- •15, patients with a history of prior irradiation of the intended target therapy site.
研究者
相似试验
进行中（未招募）
1 期
Enzalutamide and hypofractionated radiation therapy in intermediate-risk localized prostate cancerMedDRA version: 19.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004617-25-ESFundación Canaria de Investigación Sanitarias
进行中（未招募）
1 期
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate CancerNCT02023463Thomas Jefferson University25
招募中
2 期
Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancerRecurrent prostate cancerC61Malignant neoplasm of prostateDRKS00025948niversitätsklinikum Freiburg49
进行中（未招募）
1 期
Evaluation of radiotherapy in combination with pembrolizumab in patients with recurrent prostate cancer after radical prostatectomyRecurrent prostate cancer - Patients with biochemical recurrence (BCR) or persisting prostate-specifiv antigen (PSA) after radical prostatectomy (RP)EUCTR2021-001291-42-DEniversitätsklinikum Freiburg49
终止
2 期
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate CancerPelvic NodalProstatic NeoplasmsNCT02508636University of California, San Francisco11